San Diego, CA, United States of America

Naveen Dakappagari

USPTO Granted Patents = 1 

 

Average Co-Inventor Count = 4.0

ph-index = 1


Company Filing History:


Years Active: 2009

Loading Chart...
Loading Chart...
1 patent (USPTO):Explore Patents

Title: Innovations of Naveen Dakappagari in Cancer Research

Introduction

Naveen Dakappagari is a prominent inventor based in San Diego, California. He has made significant contributions to the field of cancer research through his innovative work on antibodies. His research focuses on developing methods to select antibodies that can effectively target cancer cells while sparing normal human cells.

Latest Patents

Naveen holds a patent for "Antibodies against cancer produced using masked cancer cells as immunogen." This patent outlines methods for selecting antibodies with desirable characteristics from a diverse population. Specifically, it provides techniques for identifying antibodies that bind to cancer cells but do not interact with human red or white blood cells or normal tissue cells. The antibodies developed through this research have potential applications in both therapeutic and diagnostic settings.

Career Highlights

Naveen Dakappagari is currently employed at Alexion Pharmaceuticals, Inc., where he continues to advance his research in immunology and cancer treatment. His work is instrumental in the development of novel therapeutic strategies aimed at improving patient outcomes in cancer care.

Collaborations

Some of Naveen's notable coworkers include Katherine S Bowdish and Hong Xin, who collaborate with him on various research projects. Their combined expertise contributes to the innovative environment at Alexion Pharmaceuticals.

Conclusion

Naveen Dakappagari's contributions to cancer research through his patented innovations highlight the importance of targeted therapies in modern medicine. His work exemplifies the potential of scientific research to make a meaningful impact on healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…